Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor de Ledinghen

Showing results (81-90 of 175) with videos related to

Pageof 18
Sort By:
European Journal of Gastroenterology & Hepatology|October 19, 2004
Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosisArmand Abergel, Claude Darcha, Michèle Chevallier, et al.
Journal of Hepatology|January 19, 2018
Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxificationMaja Thiele, Vanessa Rausch, Gabriele Fluhr, et al.
Nature Communications|August 26, 2023
Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis testsJérôme Boursier, Marine Roux, Charlotte Costentin, et al.
Hepatology (Baltimore, Md.)|October 24, 2006
Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndromeAurélie Plessier, Annie Sibert, Yann Consigny, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 4, 2009
The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosisJérôme Boursier, Julien Vergniol, Apollinaire Sawadogo, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2011
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatmentVéronique Loustaud-Ratti, Paul Carrier, Annick Rousseau, et al.
JHEP Reports : Innovation in Hepatology|May 6, 2022
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviorsPatrizia Carrieri, Fabrice Carrat, Vincent Di Beo, et al.
Haematologica|July 14, 2018
The <i>SLC40A1</i> R178Q mutation is a recurrent cause of hemochromatosis and is associated with a novel pathogenic mechanismChandran Ka, Julie Guellec, Xavier Pepermans, et al.
Journal of Hepatology|August 18, 2020
Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related deathMathieu Chalouni, Stanislas Pol, Philippe Sogni, et al.
Annals of Internal Medicine|February 1, 2021
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled TrialChristophe Bureau, Dominique Thabut, Caroline Jezequel, et al.
Pageof 18

Showing results (81-90 of 175) with videos related to

Sort By:
Pageof 18
European Journal of Gastroenterology & Hepatology|October 19, 2004
Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosisArmand Abergel, Claude Darcha, Michèle Chevallier, et al.
Journal of Hepatology|January 19, 2018
Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxificationMaja Thiele, Vanessa Rausch, Gabriele Fluhr, et al.
Nature Communications|August 26, 2023
Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis testsJérôme Boursier, Marine Roux, Charlotte Costentin, et al.
Hepatology (Baltimore, Md.)|October 24, 2006
Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndromeAurélie Plessier, Annie Sibert, Yann Consigny, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 4, 2009
The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosisJérôme Boursier, Julien Vergniol, Apollinaire Sawadogo, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|May 21, 2011
Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatmentVéronique Loustaud-Ratti, Paul Carrier, Annick Rousseau, et al.
JHEP Reports : Innovation in Hepatology|May 6, 2022
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviorsPatrizia Carrieri, Fabrice Carrat, Vincent Di Beo, et al.
Haematologica|July 14, 2018
The <i>SLC40A1</i> R178Q mutation is a recurrent cause of hemochromatosis and is associated with a novel pathogenic mechanismChandran Ka, Julie Guellec, Xavier Pepermans, et al.
Journal of Hepatology|August 18, 2020
Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related deathMathieu Chalouni, Stanislas Pol, Philippe Sogni, et al.
Annals of Internal Medicine|February 1, 2021
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled TrialChristophe Bureau, Dominique Thabut, Caroline Jezequel, et al.
Pageof 18